Literature DB >> 19714261

Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors.

Jatinder S Josan1, Josef Vagner, Heather L Handl, Rajesh Sankaranarayanan, Robert J Gillies, Victor J Hruby.   

Abstract

Heteromultivalency provides a route to increase binding avidity and to high specificity when compared to monovalent ligands. The enhanced specificity can potentially serve as a unique platform to develop diagnostics and therapeutics. To develop new imaging agents based upon multivalency, we employed heterobivalent constructs of optimized ligands. In this report, we describe synthetic methods we have developed for the preparation of heterobivalent constructs consisting of ligands targeted simultaneously to the melanocortin receptor, hMC4R, and the cholecystokinin receptors, CCK-2R. Modeling data suggest that a linker distance span of 20-50 Å is needed to crosslink these two G-protein coupled receptors (GPCRs). The two ligands were tethered with linkers of varying rigidity and length, and flexible polyethylene glycol based PEGO chain or semi-rigid [poly(Pro-Gly)] linkers were employed for this purpose. The described synthetic strategy provides a modular way to assemble ligands and linkers on solid-phase supports. Examples of heterobivalent ligands are provided to illustrate the increased binding avidity to cells that express the complementary receptors.

Entities:  

Year:  2008        PMID: 19714261      PMCID: PMC2732021          DOI: 10.1007/s10989-008-9150-3

Source DB:  PubMed          Journal:  Int J Pept Res Ther        ISSN: 1573-3149            Impact factor:   1.931


  16 in total

Review 1.  Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.

Authors:  Daniel Fourmy; Chantal Escrieut; Elodie Archer; Céline Galès; Véronique Gigoux; Bernard Maigret; Luis Moroder; Sandrine Silvente-Poirot; Jean Martinez; Jean-Alain Fehrentz; Lucien Pradayrol
Journal:  Pharmacol Toxicol       Date:  2002-12

2.  Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH.

Authors:  Josef Vagner; Heather L Handl; Robert J Gillies; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 3.  Hitting multiple targets with multimeric ligands.

Authors:  Heather L Handl; Josef Vagner; Haiyong Han; Eugene Mash; Victor J Hruby; Robert J Gillies
Journal:  Expert Opin Ther Targets       Date:  2004-12       Impact factor: 6.902

4.  Targeting drugs to combinations of receptors: a modeling analysis of potential specificity.

Authors:  Michael R Caplan; Elena V Rosca
Journal:  Ann Biomed Eng       Date:  2005-08       Impact factor: 3.934

5.  Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor.

Authors:  Heather L Handl; Josef Vagner; Henry I Yamamura; Victor J Hruby; Robert J Gillies
Journal:  Anal Biochem       Date:  2005-08-15       Impact factor: 3.365

6.  Expression-driven reverse engineering of targeted imaging and therapeutic agents.

Authors:  Robert J Gillies; Victor J Hruby
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

7.  Rigid linkers for bioactive peptides.

Authors:  Josef Vagner; Heather L Handl; Yasunari Monguchi; Umasish Jana; Lucinda J Begay; Eugene A Mash; Victor J Hruby; Robert J Gillies
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

Review 8.  Lanthanide-based luminescent assays for ligand-receptor interactions.

Authors:  Heather L Handl; Robert J Gillies
Journal:  Life Sci       Date:  2005-02-19       Impact factor: 5.037

9.  Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions.

Authors:  Heather L Handl; Josef Vagner; Henry I Yamamura; Victor J Hruby; Robert J Gillies
Journal:  Anal Biochem       Date:  2004-07-15       Impact factor: 3.365

10.  Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).

Authors:  Heather L Handl; Rajesh Sankaranarayanan; Jatinder S Josan; Josef Vagner; Eugene A Mash; Robert J Gillies; Victor J Hruby
Journal:  Bioconjug Chem       Date:  2007-06-26       Impact factor: 4.774

View more
  18 in total

1.  Cell-specific targeting by heterobivalent ligands.

Authors:  Jatinder S Josan; Heather L Handl; Rajesh Sankaranarayanan; Liping Xu; Ronald M Lynch; Josef Vagner; Eugene A Mash; Victor J Hruby; Robert J Gillies
Journal:  Bioconjug Chem       Date:  2011-06-16       Impact factor: 4.774

2.  Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Natalie M Barkey; Narges K Tafreshi; Jatinder S Josan; Channa R De Silva; Kevin N Sill; Victor J Hruby; Robert J Gillies; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2011-11-10       Impact factor: 7.446

3.  Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.

Authors:  Jatinder S Josan; Channa R De Silva; Byunghee Yoo; Ronald M Lynch; Mark D Pagel; Josef Vagner; Victor J Hruby
Journal:  Methods Mol Biol       Date:  2011

4.  Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor.

Authors:  Steve M Fernandes; Yeon Sun Lee; Robert J Gillies; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2014-10-02       Impact factor: 3.641

5.  Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.

Authors:  Justin Hoffman; Andrea N Flynn; Dipti V Tillu; Zhenyu Zhang; Renata Patek; Theodore J Price; Josef Vagner; Scott Boitano
Journal:  Bioconjug Chem       Date:  2012-10-08       Impact factor: 4.774

Review 6.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

Review 7.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

8.  Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.

Authors:  Andrea N Flynn; Justin Hoffman; Dipti V Tillu; Cara L Sherwood; Zhenyu Zhang; Renata Patek; Marina N K Asiedu; Josef Vagner; Theodore J Price; Scott Boitano
Journal:  FASEB J       Date:  2013-01-04       Impact factor: 5.191

Review 9.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

10.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.